IntelGenx Technologies Corp. IGX.TO
Quote time unavailable
Day range unavailable
52-week range unavailable
- Market cap
- 41.92M
- Revenue (ttm)
- 1.05M
- Shares out
- 174.66M
- Beta
- 2.54
Key statistics
- Enterprise value
- 57.60M
- PEG ratio
- 0.00
- Price / sales
- 39.88
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.40%
- Free cash flow
- -2.98M
- Total cash
- 772.00K
- Total debt
- 16.46M
- Return on equity
- 0.00%
- Short % of float
- 0.01%
- 50-day average
- 0.2343
- 200-day average
- 0.20765
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- intelgenx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on IGX.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BECHARD ROBERT J | Officer | Purchase | Jan 21, 2016 | 10,000 |
| BOUDREAU BERNARD J | Director | Purchase | Mar 31, 2021 | 175,000 |
| BOUDREAU J BERNARD | Director | Purchase | Jan 21, 2016 | 0 |
| DURHAM JOHN EDWARD | Officer | Purchase | Oct 6, 2016 | 13,000 |
| GODIN ANDRE | President | Purchase | Sep 28, 2022 | 308,399 |
| KENNY TOMMY | Officer | Purchase | Sep 25, 2022 | 138,500 |
